Hydra Biosciences : Partnering Opportunities : Statement of Intent - Hydra Biosciences, biopharmaceutical company, Cambridge, Massachusetts, novel drugs important human diseases, major therapeutic areas, pain, cardiovascular disease, transient receptor potential (TRP) ion channels, molecular regeneration.

Hydra Biosciences has a platform technology in ion channels that will produce multiple product opportunities over the coming years. Hydra's early business strategy is to utilize productive collaborative partnerships to build product research and development capability to drive the development of its product pipeline. Hydra will capitalize on its early research successes in ion channels by entering into partnerships on its lead programs to drive them through development and commercialization with the help of its partners.

Hydra has a pipeline of programs focused on a novel family of ion channels, called Transient Receptor Potential (TRP) channels, which play a role in a variety of different disease states. Hydra is seeking a global partner to help advance the company's TRP channel program which is currently developing drugs for the treatment of pain, one of the largest pharmaceutical markets in the world. With a partner, Hydra will bring to market a first in class, best in class new medicine for the treatment of acute and chronic pain.